Neurogenic Detrusor Overactivity: Escalate, Switch, or Inject
A spinal cord injury patient's oxybutynin is already near its practical ceiling and still failing him. The disagreement is whether the fix is a second drug, a substituted one, or leaving oral therapy behind entirely.
Derek M., a 34-year-old supply-chain coordinator who works from his kitchen table and still makes every Thursday-night wheelchair basketball scrimmage, has lived with a T10 complete spinal cord injury for six years, since a motorcycle collision on a stretch of highway he now drives past twice a week without much thought. He performs clean intermittent catheterization five times a day and has been on oxybutynin extended-release 15mg — close to the ceiling most clinicians will push it — for the neurogenic detrusor overactivity that came with the injury. It has never fully controlled him: he still leaks two to three times most days between catheterizations, unpredictably enough that he keeps a change of clothes at his desk. The dry mouth bothers him more than the leakage does in his own account of it — a real problem for someone who spends four hours a day on client calls, throat clearing between sentences in a way he has started to notice clients notice too.
His most recent urodynamic study showed a maximum cystometric capacity of 240mL and involuntary detrusor contractions beginning at 140mL — a bladder that fills and contracts well before the volume a catheterization-timed adult usually tolerates, the actual physiologic reason his current regimen keeps falling short rather than any error in how he uses it. Krhut et al.'s placebo-controlled trial of mirabegron enrolled 78 patients with spinal cord injury or multiple sclerosis, 66 of whom reached final analysis, and found real gains in bladder compliance and in volume at first detrusor contraction — the second of which is exactly the measurement failing him. What that trial cannot settle is how much of its result belongs to someone like him. Akkoc's systematic review of the wider literature reports mirabegron clinically effective in spinal cord injury while the randomized studies that measured urodynamics in that group did not show matching urodynamic gains, and Welk's later individual-patient meta-analysis, pooling the only two placebo-controlled trials, found improvement in multiple sclerosis and spinal cord injury alike — but the clearest gains sat with patients whose injuries were incomplete, or whose lesions fell below T7. Derek's lesion is below T7 and complete, which puts him on the favorable side of one of those two markers and the wrong side of the other. He is not outside the studied population; he sits in the part of it the data speak least confidently about — which is the position the room has to decide from, with a 34-year-old in front of it and the question being not whether mirabegron works but how many drugs he should still be on at sixty.
Bladder clinic, six years post-injury
Add mirabegron to what he's already on rather than substitute it. His urodynamics describe a bladder that needs more total detrusor suppression, not less — first contraction at 140 of 240mL is a severe pattern, and Krhut's trial showed real compliance and capacity gains layered on top of comparable severity. The dry mouth is a genuine cost, but it's a cost of the oxybutynin he's already taking; adding a second, differently-acting drug doesn't have to make that worse.
I'd rather solve for more bladder control first and negotiate the anticholinergic dose down later, once we know his continence can hold without it.
I don't think simply stacking two drugs' side-effect burdens on a 34-year-old is a small decision — this is a man who may be on whatever we choose for another fifty years.
The compliance gains Dr. Reyes is describing came from a trial pool that mixed spinal cord injury with multiple sclerosis, and I'd be careful about the mechanism story people attach to that. Mirabegron doesn't act centrally at all — it's a beta-3 agonist working on detrusor smooth muscle directly, which is precisely why Akkoc's review can report it clinically effective in spinal cord injury while the urodynamic endpoints in the same group stayed flat. Welk's individual-patient meta-analysis is the more useful read for us: the clearest gains were in incomplete injuries and lesions below T7, and Derek's injury is complete. I'd rather taper the oxybutynin down while introducing mirabegron and watch what happens to his diary, not add it blind. If his control holds through the taper, we've learned the anticholinergic was doing less than we assumed and we've spared him decades of dry mouth for nothing. If it doesn't, we've lost a few weeks, not the drug.
You're both arguing about which oral combination to try next, and I think that's the wrong axis. A bladder that contracts at 140 of 240mL, on a near-maximal anticholinergic already, is describing a pharmacologic ceiling, not a dosing error — and the two pivotal onabotulinumtoxinA trials were built for exactly this population. The retention risk that trial showed rising with dose isn't a new burden for Derek specifically; he already catheterizes five times a day. There's no oral regimen left to protect him from a risk he's already living with.
I take the taper-and-test logic seriously as a way to learn something about his current regimen. I just don't think we need to learn it before offering him the option that's actually proven in his population.
Agreed: add mirabegron 50mg to his current oxybutynin XL, six-week bladder diary, urodynamic re-check if the diary doesn't show real improvement.
Continue both agents; revisit the anticholinergic dose only if dry mouth remains a dominant complaint.
The pharmacologist and physiatrist expect a taper trial next; the urologist would move straight to onabotulinumtoxinA instead.
Not agreed, and left explicit rather than smoothed over: whether adding mirabegron without touching the oxybutynin answers anyone's actual question. The pharmacologist wanted the taper run alongside the new drug precisely so the batch of information it would produce — how much the anticholinergic is still contributing after six years — doesn't get lost the moment a second agent masks it, and considers today's plan the one option that guarantees they will still not know at six weeks. The urologist's objection runs the opposite direction: he reads the urodynamics as already describing a pharmacologic ceiling and sees the whole oral sequence as a detour that costs Derek a season before arriving where the population-matched evidence already points. The physiatrist's view carried today — solve for continence first, negotiate exposure afterward — but neither of the other two conceded the reasoning, only the sequencing.